A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (Corifollitropin Alfa) in Combination With Human Chorionic Gonadotropin (hCG) for Initiation or Restoration of Puberty as Assessed by Increased Testicular Volume in Adolescent Males 14 to <18 Years Old With Hypogonadotropic Hypogonadism (MK-8962-043)
Latest Information Update: 05 May 2022
At a glance
- Drugs Chorionic gonadotropin (Primary) ; Corifollitropin alfa (Primary)
- Indications Hypogonadism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Organon
- 12 May 2020 Status changed from active, no longer recruiting to completed.
- 22 Apr 2019 Planned End Date changed from 25 May 2020 to 29 Apr 2020.
- 22 Apr 2019 Planned primary completion date changed from 25 May 2020 to 29 Apr 2020.